+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020

  • ID: 5189100
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 94 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlycoMimetics Inc
  • Hartis Pharma SA
  • KM Biologics Co Ltd
  • NicOx SA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3, 1 and 4 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlycoMimetics Inc
  • Hartis Pharma SA
  • KM Biologics Co Ltd
  • NicOx SA
Introduction
  • Report Coverage
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development
  • Asklepion Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Cyclerion Therapeutics Inc
  • Global Blood Therapeutics Inc
  • GlycoMimetics Inc
  • Hartis Pharma SA
  • KM Biologics Co Ltd
  • NicOx SA
  • Novartis AG
  • Prolong Pharmaceuticals LLC
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles

apadamtase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
apixaban - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
crizanlizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
HRT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
inclacumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
L-Citrulline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
naproxcinod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
olinciguat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
rivipansel sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Sanguinate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ticagrelor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones
  • Featured News & Press Releases
  • Oct 05, 2020: FDA grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for treatment of sickle cell disease
  • Jun 12, 2020: New efficacy and biomarker data from Rivipansel phase 3 RESET trial to be presented at Sickle Cell meeting
  • Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states
  • Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients
  • Aug 05, 2019: Pfizer’s RESET trial of rivipansel fails to meet endpoints
  • Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
  • May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease
  • Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
  • Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting
  • Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting
  • Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
  • Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
  • Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
  • Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
  • Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Asklepion Pharmaceuticals LLC, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by GlycoMimetics Inc, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Hartis Pharma SA, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by KM Biologics Co Ltd, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NicOx SA, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H2 2020
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Asklepion Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Cyclerion Therapeutics Inc
  • Global Blood Therapeutics Inc
  • GlycoMimetics Inc
  • Hartis Pharma SA
  • KM Biologics Co Ltd
  • NicOx SA
  • Novartis AG
  • Prolong Pharmaceuticals LLC
Note: Product cover images may vary from those shown
Adroll
adroll